OXBDF News and Press, Oxford BioMedica From 03/08/21

SIOX has promising results in its gene therapy programs. Not only is the Parkinson's disease program showing impressive results, but recent developments on the rare disease front are also very encouraging. I work through these developments and then turn to the company's valuation ...

LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emer...

AXGT has promising gene therapy results in Parkinson's Disease. If future clinical results mimic the early ones, AXGT could have an addressable market of over $7.5 billion. Trading at an enterprise value of $143M, the risk reward ratio is enticing.  Nonetheless, investors sho...

Oxford Biomedica plc (OXBDF) Q1 2020 Earnings Conference Call Sep 17, 2020 8:00 AM ET Company Participants Catherine Isted - Head, Corporate Development and Investor Relations John Dawson - Chief Executive Officer Stuart Paynter - Chief Financial Officer Conference Call Parti...

Privately-held Papyrus Therapeutics and Oxford Biomedica ( OTCPK:OXBDF -0.3% ) have signed a research collaboration , on the development of a CAR-T product candidate incorporating Papyrus' PYTX-002, a gene replacement therapy for solid tumors. More news on:...

The following slide deck was published by Oxford Biomedica plc in conjunction with their 2020 Q2 earnings Read more ...

Oxford Biomedica plc ( OTCPK:OXBDF ) has signed an 18-month supply agreement under a three-year master supply and development contract with AstraZeneca (NYSE: AZN ) for the large-scale commercial manufacture of COVID-19 vaccine AZD1222. More news on: Oxford Biomedica plc, AstraZeneca...

Oxford Biomedica ( OTCPK:OXBDF )   inks a new development, manufacture & license agreement with Beam Therapeutics (NASDAQ: BEAM ) for LentiVector platform for next generation CAR-T Therapeutics. More news on: Beam Therapeutics Inc., Oxford Biomedica plc, Healthcare stocks...

Results from a Phase 1/2 clinical trial at five sites in the UK evaluating the safety and immunogenicity of Oxford University's chimpanzee adenovirus-vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 [dubbed AZD1222 at licensee AstraZeneca ( AZN -0.8% )] in 1077 healthy volunteers sho...

Results from a 508-subject Phase 1 clinical trial, just published online in The Lancet , showed that AstraZeneca's ( AZN -0.1% ) COVID-19 vaccine candidate showed a seroconversion rate at high as 97% at day 28. More news on: AstraZeneca PLC, Oxford Biomedica plc, Healthcare stocks ne...